Vigon-Hernandez, LorenaLuna, AlejandroGalán Burgos, MiguelRodríguez-Mora, SaraFuertes, DanielMateos, ElenaPiris-Villaespesa, MiguelBautista, GuiomarSan José, EstherRivera-Torres, JoséSteegmann, Juan LuisDe Ory, Fernando dePerez-Olmeda, MayteAlcamí, JoséPlanelles, VicenteLopez-Huertas, Maria RosaGarcía-Gutiérrez, ValentínCoiras, Mayte2021-01-132021-01-132020-12-25J Clin Med . 2020 Dec 25;10(1):42.http://hdl.handle.net/20.500.12105/11606BCR-ABL is an aberrant tyrosine kinase responsible for chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs) induce a potent antileukemic response mostly based on the inhibition of BCR-ABL, but they also increase the activity of Natural Killer (NK) and CD8+ T cells. After several years, patients may interrupt treatment due to sustained, deep molecular response. By unknown reasons, half of the patients relapse during treatment interruption, whereas others maintain a potent control of the residual leukemic cells for several years. In this study, several immunological parameters related to sustained antileukemic control were analyzed. According to our results, the features more related to poor antileukemic control were as follows: low levels of cytotoxic cells such as NK, (Natural Killer T) NKT and CD8±TCRγβ+ T cells; low expression of activating receptors on the surface of NK and NKT cells; impaired synthesis of proinflammatory cytokines or proteases from NK cells; and HLA-E*0103 homozygosis and KIR haplotype BX. A Random Forest algorithm predicted 90% of the accuracy for the classification of CML patients in groups of relapse or non-relapse according to these parameters. Consequently, these features may be useful as biomarkers predictive of CML relapse in patients that are candidates to initiate treatment discontinuation.engVoRchronic myeloid leukemiaimmunological responsetreatment-free remissionAtribución 4.0 Internacional3337557210110.3390/jcm100100422077-0383Journal of clinical medicineopen access